Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3U7SZ)

• Drug Name: Romiplostim Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Thrombocytopenia	3B64	Approved	[1] , [2]
Multiple myeloma	2A83	Phase 2	[3] , [4] , [5]
Myelodysplastic syndrome	2A37	Phase 2	[1] , [6]

• Cross-matching ID:
  PubChem CID: 5329098
  ChEBI ID: CHEBI:91083
  CAS Number: CAS 194413-58-6
  TTD Drug ID: DM3U7SZ

Molecule-Related Drug Atlas

Drug(s) Targeting Thrombopoietin receptor (MPL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eltrombopag	DMOGFIX	Thrombocytopenia	3B64	Approved	[6]
Revolade/Promacta	DM8LRU2	Idiopathic thrombocytopenic purpura	3B64.10	Approved	[12]
Lusutrombopag	DMH6IKO	Thrombocytopenia	3B64	Approved	[13]
As-1670542	DMV05SW	Thrombocytopenia	3B64	Approved	[14]
LGD-4665	DM9T8A2	Immune thrombocytopenic purpura	3B64.13	Phase 2	[6]
BVI-007	DM43GPX	Myocardial infarction	BA41-BA43	Phase 1	[14]
NIP-004	DM0PYEQ	Thrombocytopenia	3B64	Phase 1	[15]
RhTPO	DMCV0BZ	Idiopathic thrombocytopenic purpura	3B64.10	Discontinued in Phase 3	[6]
Totrombopag	DM6SUDC	Thrombocytopenia	3B64	Discontinued in Phase 1	[12]
Promegapoietin	DMS4FG0	Bone marrow transplantation	QB63.6	Terminated	[16]

Drug(s) Targeting Aryl hydrocarbon receptor (AHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RVT-505	DM3C9F8	Atopic dermatitis	EA80	Phase 2	[17]
IK-175	DMDU54Y	Urothelial carcinoma	2C92.0	Phase 1	[18]
BAY 2416964	DMD9N12	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
CB7993113	DMJUQ6E	Solid tumour/cancer	2A00-2F9Z	Preclinical	[20]
2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester	DMIS1G7	Glioma	2A00.0	Preclinical	[21]
6-Formylindolo[3,2-b]carbazole	DMN84RM	Dermatitis	EA80-EA89	Investigative	[22]
CH-223191	DMMJZYC	Solid tumour/cancer	2A00-2F9Z	Investigative	[23]

Drug(s) Targeting Fibroblast growth factor receptor 1 (FGFR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[24]
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[25]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[26]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[27]
Rosiglitazone + metformin	DMPIDXT	Diabetic complication	5A2Y	Phase 3	[28]
BGJ398	DMNKBEC	Cholangiocarcinoma	2C12.10	Phase 3	[29]
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[30]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[31]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[32]
AM-001	DMGVQI8	Actinic keratosis	EK90.0	Phase 2	[33]

Drug(s) Targeting Platelet-derived growth factor receptor alpha (PDGFRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[34]
Olaratumab	DMNYOIX	Soft tissue sarcoma	2B57	Approved	[35]
Avapritinib	DMK2GZX	Gastrointestinal stromal tumour	2B5B	Approved	[36]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[26]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[37]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[38]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[39]
MP470	DMELUAK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[40]
MEDI-575	DMI9WVM	Glioblastoma multiforme	2A00.0	Phase 2	[41]
Pyridine derivative 18	DMBZMYT	N. A.	N. A.	Patented	[42]

Drug(s) Targeting Tyrosine-protein kinase Kit (KIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[28]
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[43]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[44]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[44]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[45]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[46]
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[34]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[38]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[39]
MP470	DMELUAK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[40]

Drug(s) Targeting Platelet-derived growth factor receptor beta (PDGFRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[43]
Becaplermin	DM1R5X4	Diabetic complication	5A2Y	Approved	[16]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[26]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[38]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[39]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[47]
SNN-0031	DM2X3BR	Brain injury	NA07.Z	Phase 1/2	[48]
TAK-593	DMNFZOT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[49]
Pyridine derivative 18	DMBZMYT	N. A.	N. A.	Patented	[42]
PMID25656651-Compound-21a	DMCKAON	N. A.	N. A.	Patented	[50]

Drug(s) Targeting Proto-oncogene c-Ret (RET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[44]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[44]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[28]
Selpercatinib	DMZR15V	Non-small-cell lung cancer	2C25.Y	Approved	[51]
Pralsetinib	DMWU0I2	Non-small-cell lung cancer	2C25.Y	Approved	[52]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[53]
CEP-32496	DMAO04B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[32]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[54]
GSK3179106	DM2KCIP	Inflammatory bowel disease	DD72	Phase 1	[55]
BOS172738	DM9L0D8	Solid tumour/cancer	2A00-2F9Z	Phase 1	[56]

Drug(s) Targeting VEGFR1 messenger RNA (VEGFR1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VATALANIB	DMY0UEQ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[57]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[47]
Sirna-027	DMZTQD8	Exudative age-related macular degeneration	9B78.3Z	Phase 1/2	[58]
PMID22765894C8h	DMH5RFU	Discovery agent	N.A.	Investigative	[59]
2-(1H-indazol-3-yl)-1H-benzo[d]imidazole	DM0CSH8	Discovery agent	N.A.	Investigative	[60]
AAL-993	DM35RFH	Discovery agent	N.A.	Investigative	[57]
PMID17935989C25	DML8ZBR	Discovery agent	N.A.	Investigative	[61]
2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile	DMX6QMT	Discovery agent	N.A.	Investigative	[62]
4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide	DMI3OR9	Discovery agent	N.A.	Investigative	[63]
(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine	DMQWD75	Discovery agent	N.A.	Investigative	[62]

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[43]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[44]
Sunitinib	DMCBJSR	Gastrointestinal cancer	2C11	Approved	[64]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[65]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[28]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[45]
Cabozantinib	DMIYDT4	Thyroid cancer	2D10	Approved	[66]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[67]
Lenvatinib	DMB1IU4	Thyroid cancer	2D10	Approved	[68]
Yn-968D1	DMMP3Y2	Breast cancer	2C60-2C65	Approved	[69]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aryl hydrocarbon receptor (AHR)	TT037IE	AHR_HUMAN	Modulator	[4] , [7]
Fibroblast growth factor receptor 1 (FGFR1)	TTRLW2X	FGFR1_HUMAN	Inhibitor	[8]
Platelet-derived growth factor receptor alpha (PDGFRA)	TT8FYO9	PGFRA_HUMAN	Inhibitor	[9]
Platelet-derived growth factor receptor beta (PDGFRB)	TTI7421	PGFRB_HUMAN	Inhibitor	[9]
Proto-oncogene c-Ret (RET)	TT4DXQT	RET_HUMAN	Inhibitor	[10]
Thrombopoietin receptor (MPL)	TTIHYA4	TPOR_HUMAN	Modulator	[2]
Tyrosine-protein kinase Kit (KIT)	TTX41N9	KIT_HUMAN	Inhibitor	[11]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Inhibitor	[8]
VEGFR1 messenger RNA (VEGFR1 mRNA)	TT1VAUK	VGFR1_HUMAN	Inhibitor	[11]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6974).
• [2] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5056).
• [4] A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.
• [5] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [6] Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
• [7] SU5416, a VEGF Receptor Inhibitor and Ligand of the AHR, Represents a New Alternative for Immunomodulation
• [8] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [9] Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
• [10] Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
• [11] New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
• [12] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [13] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
• [15] A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood. 2006 Jun 1;107(11):4300-7.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] Clinical pipeline report, company report or official report of Ikena Oncology.
• [19] ClinicalTrials.gov (NCT04069026) A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [20] In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol. 2014 Nov;86(5):593-608.
• [21] 1'H-Indole-3'-Carbonyl-Thiazole-4-Carboxylic Acid Methyl Ester Blocked Human Glioma Cell Invasion via Aryl Hydrocarbon Receptor's Regulation of Cytoskeletal Contraction. Biomed Res Int. 2020 Oct 3;2020:2616930.
• [22] 6-Formylindolo(3,2-b)carbazole induced aryl hydrocarbon receptor activation prevents intestinal barrier dysfunction through regulation of claudin-2 expression. Chem Biol Interact. 2018 May 25;288:83-90.
• [23] Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol. 2006 Jun;69(6):1871-8.
• [24] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [25] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [26] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [27] Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
• [28] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [29] Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.
• [30] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
• [31] AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56.
• [32] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [33] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917)
• [34] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [35] A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
• [36] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [37] The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
• [38] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [39] National Cancer Institute Drug Dictionary (drug id 452042).
• [40] Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
• [41] Clinical pipeline report, company report or official report of MedImmune (2011).
• [42] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [43] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [44] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [45] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [46] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [47] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [48] Company report (Neuronova)
• [49] Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
• [50] Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
• [51] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [52] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [53] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
• [54] Clinical pipeline report, company report or official report of Turning Point Therapeutics.
• [55] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [56] National Cancer Institute Drug Dictionary (drug name Zeteletinib).
• [57] Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9.
• [58] 2011 Pipeline of Sirna Therapeutics.
• [59] The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
• [60] Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9.
• [61] Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and prelimina... Bioorg Med Chem Lett. 2007 Dec 1;17(23):6593-601.
• [62] Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
• [63] Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
• [64] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [65] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [66] Clinical pipeline report, company report or official report of Exelixis (2011).
• [67] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [68] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [69] YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011 Jul;102(7):1374-80.